Grants and Contracts Details
Description
Confidential Human Clinical Trial
Study objectives
13-LUN-92-CRAB (10-001) Phase I study of mTOR inhibition in NSCLC
PI: Dennie V. Jones, MD
Primary
• To define the Maximum Tolerated Dose (MTD) and Recommended Phase Two Dose (RPTD) of the combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with Stage IV non-squamous NSCLC.
Secondary
• To describe the safety profile of everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC.
• To describe any antitumor efficacy associated with administration of everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC.
• To assess the suitability of the MTD as the RTPD in patients with Stage IV non-squamous NSCLC
Status | Finished |
---|---|
Effective start/end date | 12/1/13 → 1/21/15 |
Funding
- Cancer Research and Biostatistics: $2.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.